Please note: Any medical or genetic information present in this entry is not intended as a diagnosis of your problem, but rather is provided as a helpful guide for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care. Information is not necessarily complete. Please see your doctor for diagnosis and treatment.

Please note: DNAtraffic database is the project under construction and information on this page is not finished yet.

Cycloleucine


ACCESSION NB: DB04620


TYPE: small molecule


GROUP: experimental


DESCRIPTION:
Cycloleucine is an amino acid formed by cyclization of leucine. Cycloleucine is a non-metabolisable amino acid and is a specific and reversible inhibitor of nucleic acid methylation, and as such is widely used in biochemical experiments. [Wikipedia] Cycloleucine, a non-metabolizable amino acid analogue produces status spongiosus in cerebral white matter of rats and mice as well as a distinctive lesion of astrocytes. Its mechanisms of action include competition with natural amino acids from transport across the blood-brain barrier leading to inhibition of entry of circulating amino acids into brain, interference with ribosomal RNA maturation, and blockage of transmethylation reactions, including the conversion of homocystine to methionine. Cycloleucine also affects the kidney, producing aminoaciduria.

VOLUME OF DISTRIBUTION: Not Available

CATEGORIES:
Antineoplastic Agents Immunosuppressive Agents

ABSORPTION: Not Available

INDICATION:
Not Available

PHARMACODYNAMICS:
Cycloleucine has cytostatic, immunosuppressive and antineoplastic activities.

MECHANISM OF ACTION:
Not Available

PROTEIN BINDING:
Not Available

TOXICITY:
Oral, mouse: LD50 = 309 mg/kg; oral, rat: LD50 = 290 mg/kg

AFECTED ORGANISMS:
Humans and other mammals